Bronchitis, Chronic, Bronchial Diseases
Conditions
Keywords
Non-Interventional, Observational, NIS, Moxifloxacin, MXF, Avelox, AECB
Brief summary
The observation period for each patient covered an initial treatment period with Avelox® plus optional 2 long-term follow-up periods (6 and 12 months).For each patient, the physician documented data at any initial visit (baseline) and at least one short-term follow-up visit (=initial treatment period).Optionally, long-term follow-ups (6 and 12 months) were documented, and a patient questionnaire was filled in.
Interventions
AECB patients under daily life treatment receiving moxifloxacin according to the local product information.
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Outpatients with diagnosis of AECB and decision taken by the investigator to prescribe moxifloxacin
Exclusion criteria
*
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of impact of AECB on the patient and the community as well as effect and safety of a treatment with moxifloxacin tablets in daily life clinical practice | During documentation at baseline and at at least one short-term follow-up visit; at maximum two short-term (within ca. 14 days) and two long-term follow-up visits (after ca. 6 and 12 months). |
Secondary
| Measure | Time frame |
|---|---|
| Course of symptom relief | During documentation of up to two short-term follow-up visits (within ca. 14 days) |
| Speed of return to normal daily life activities | During documentation of the last short-term follow-up visit (after ca. 14 days) |
| Adverse events collection | Throughout the entire study, whenever Adverse Events occur |
| Evaluation of frequency of new exacerbations | During documentation of up to two long-term follow-up visits (after ca. 6 and 12 months) |
| Progression of chronic respiratory disease | During documentation of up to two long-term follow-up visits (after ca. 6 and 12 months) |
Countries
Austria, Brazil, China, Colombia, Croatia, Egypt, El Salvador, Germany, Hong Kong, Hungary, Indonesia, Malaysia, Mexico, Morocco, Netherlands, Pakistan, Philippines, Poland, Singapore, Slovenia, South Korea, Switzerland, Taiwan, Turkey (Türkiye)
Outcome results
None listed